Modified compstatin with peptide backbone and C-terminal modifications
View Patent ↗Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. The compounds comprise compstatin analogs having a constrained backbone at position 8 (glycine) and, optionally, specific substitutions for threonine at position 13.
1. A modified compstatin peptide (ICVVQDWGHHRCT (cyclic C2-C12); SEQ ID NO:1), in which the Gly at position 8 is N-methylated to constrain the backbone conformation of the peptide at that location, and comprising one or more additional modifications selected from:
a) acetylated N-terminus;
b) Ala instead of His at position 9 of the peptide;
c) Trp or an analog of Trp instead of Val at position 4 of the peptide;
d) halogenated Trp at position 7 of the peptide;
e) Ile, Leu, Nle, N-methyl Thr or N-methyl Ile instead of Thr at position 13 of the peptide; and
f) amidated C-terminus.
2. The modified compstatin peptide of claim 1 , which includes Ala instead of His at position 9 of the peptide.
3. The modified compstatin peptide of claim 2 , which includes Trp or an analog of Trp instead of Val at position 4 of the peptide.
4. The modified compstatin peptide of claim 3 , wherein the analog of Trp at position 4 is 1-methyl Trp or 1-formyl Trp.
5. The modified compstatin peptide of claim 4 wherein the Trp at position 7 is a halogenated Trp.
6. The modified compstatin peptide of claim 1 , wherein the N-terminus of the peptide is acetylated.
7. The modified compstatin peptide of claim 1 , comprising Ile, Leu, Nle, N-methyl Thr or N-methyl Ile instead of Thr at position 13.
8. A compstatin analog that binds C3 and inhibits complement activation with at least the same potency as compstatin, comprising a peptide having a sequence of SEQ ID NO:2, which is:
Xaa1a-Xaa1b-Cys-Val-Xaa2-Gln-Asp-Xaa3-Gly-Xaa4-His-Arg-Cys-Xaa5 (cyclic C2-C 12) in which Gly at position 8 is N-methylated to constrain the backbone conformation at that location;
wherein:
Xaa1a and Xaa1b together form position 1 of the peptide;
Xaa1a is missing or is Gly, provided Xaa1b is Ile;
Xaa1b is Ile, Val, Leu, Ac-Ile, Ac-Val, or Ac-Leu;
Xaa2 is Trp or an analog of Trp, wherein the analog of Trp has increased hydrophobic character as compared with Trp;
Xaa3 is Trp or an analog of Trp comprising a chemical modification to its indole ring wherein the chemical modification increases the hydrogen bond potential of the indole ring;
Xaa4 is His, Ala, Phe or Trp; and
Xaa5 is Thr, Ile, Leu, Nle, N-methyl Thr or N-methyl Ile, wherein a carboxy terminal —OH of any of the Thr, Ile, Leu, Nle, N-methyl Thr or N-methyl Ile optionally is replaced by —NH 2 .
9. The compound of claim 8 , wherein Xaa1a is missing, Xaa1b is Ac-Ile, Xaa2 is 1-methyl-Trp or 1-formyl-Trp, Xaa3 is Trp, Xaa4 is Ala, and Xaa5 is Thr, Ile, Leu, Nle, N-methyl Thr or N-methyl Ile.
10. The compound of claim 9 , wherein Xaa5 is Ile, N-methyl Thr or N-methyl Ile.
11. The compound of claim 9 , which comprises any of SEQ ID NOS: 5, 7, 8, 9, 10 or 11.
12. The compound of claim 1 or claim 8 , further comprising an additional component that extends the in vivo retention of the compound.
13. The compound of claim 12 , wherein the additional component is polyethylene glycol (PEG).
14. The compound of claim 12 , wherein the additional component is an albumin binding small molecule.
15. The compound of claim 12 , wherein the additional component is an albumin binding peptide.
16. The compound of claim 15 , wherein the albumin binding peptide comprises the sequence RLIEDICLPRWGCLWEDD (SEQ ID NO: 14).
17. The compound of claim 15 , comprising any one of SEQ ID NOS: 5, 7, 8, 9, 10 or 11 linked to the albumin binding peptide.
18. The compound of claim 15 , wherein the compound and the albumin binding peptide are separated by a spacer.
19. The compound of claim 18 , wherein the spacer is a polyethylene glycol molecule.
20. A pharmaceutical composition comprising the compound of claim 1 or claim 8 and a pharmaceutically acceptable carrier.
21. The compound of claim 10 , wherein XaaS is N-methyl Thr or N-methyl Ile.
22. The compound of claim 21 , comprising SEQ ID NO:10.
23. The compound of claim 21 , comprising SEQ ID NO:11.